The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: A rare condition that mimics NAFLD.
cam.issuedOnline | 2018-10-11 | |
dc.contributor.author | Carter, Anna | |
dc.contributor.author | Brackley, Simon Mark | |
dc.contributor.author | Gao, Jiali | |
dc.contributor.author | Mann, Jake Peter | |
dc.contributor.orcid | Mann, Jake [0000-0002-4711-9215] | |
dc.date.accessioned | 2018-12-05T00:31:05Z | |
dc.date.available | 2018-12-05T00:31:05Z | |
dc.date.issued | 2019-01 | |
dc.description.abstract | BACKGROUND & AIMS: Lysosomal acid lipase deficiency (LAL-D) is an autosomal recessive condition that may present in a mild form (cholesteryl ester storage disease [CESD]), which mimics non-alcoholic fatty liver disease (NAFLD). It has been suggested that CESD may affect 1 in 40,000 and is under-diagnosed in NAFLD clinics. Therefore, we aimed to estimate the prevalence of LAL-D using analysis of genetic variation in LIPA. METHODS: MEDLINE and EMBASE were systematically searched for previously reported disease variants and prevalence estimates. Previous prevalence estimates were meta-analysed. Disease variants in LIPA were annotated with allele frequencies from gnomAD and combined with unreported major functional variants found in humans. Pooled ethnicity-specific prevalences for LAL-D and CESD were calculated using the Hardy-Weinberg equation. RESULTS: Meta-analysis of existing genetic studies estimated the prevalence of LAL-D as 1 per 160,000 (95% CI 1 per 65,025-761,652) using the allele frequency of c.894G>A in LIPA. A total of 98 previously reported disease variants in LIPA were identified, of which 32/98 were present in gnomAD, giving a prevalence of 1 per 307,482 (95% CI 257,672-366,865). Wolman disease was associated with more loss-of-function variants than CESD. When this was combined with 22 previously unreported major functional variants in LIPA identified in humans, the pooled prevalence of LAL-D was 1 per 177,452 (95% CI 149,467-210,683) with a carrier frequency of 1 per 421. The prevalence is lowest in those of East Asian, South Asian, and Finnish ancestry. CONCLUSION: Using 120 disease variants in LIPA, these data can reassure clinicians that LAL-D is an ultra-rare disorder. Given the therapeutic capability of sebelipase alpha, investigation for LAL-D might be included in second-line metabolic screening in NAFLD. LAY SUMMARY: Lysosomal Acid Lipase Deficiency (LAL-D) is a rare genetic condition that can cause severe liver disease, but it is difficult to diagnose and sometimes can look like simple fatty liver. It was not clear how common LAL-D was and whether many cases were being missed. To study this, we searched for all genetic mutations that could cause LAL-D, calculated how common those mutations were, and added them up. This let us estimate that LAL-D affects roughly 1 in 175,000 people. We conclude that LAL-D is a very rare condition, but it is treatable so may be included in a 'second-line' of tests for causes of fatty liver. | |
dc.format.medium | Print-Electronic | |
dc.identifier.doi | 10.17863/CAM.33632 | |
dc.identifier.eissn | 1600-0641 | |
dc.identifier.issn | 0168-8278 | |
dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/286322 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Elsevier BV | |
dc.publisher.url | http://dx.doi.org/10.1016/j.jhep.2018.09.028 | |
dc.subject | Dyslipidaemia | |
dc.subject | Epidemiology | |
dc.subject | Hepatic steatosis | |
dc.subject | Lysosomal storage disease | |
dc.subject | Meta-analysis | |
dc.subject | DNA Mutational Analysis | |
dc.subject | Diagnosis, Differential | |
dc.subject | Gene Frequency | |
dc.subject | Global Health | |
dc.subject | Humans | |
dc.subject | Liver | |
dc.subject | Mutation | |
dc.subject | Non-alcoholic Fatty Liver Disease | |
dc.subject | Prevalence | |
dc.subject | Rare Diseases | |
dc.subject | Sterol Esterase | |
dc.subject | Wolman Disease | |
dc.title | The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: A rare condition that mimics NAFLD. | |
dc.type | Article | |
dcterms.dateAccepted | 2018-09-27 | |
prism.endingPage | 150 | |
prism.issueIdentifier | 1 | |
prism.publicationDate | 2019 | |
prism.publicationName | J Hepatol | |
prism.startingPage | 142 | |
prism.volume | 70 | |
rioxxterms.licenseref.startdate | 2019-01 | |
rioxxterms.licenseref.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
rioxxterms.type | Journal Article/Review | |
rioxxterms.version | AM | |
rioxxterms.versionofrecord | 10.1016/j.jhep.2018.09.028 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- LAL-D_manuscript_repository.pdf
- Size:
- 3.25 MB
- Format:
- Adobe Portable Document Format
- Description:
- Accepted version
- Licence
- http://creativecommons.org/licenses/by-nc-nd/4.0/
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- DepositLicenceAgreementv2.1.pdf
- Size:
- 150.9 KB
- Format:
- Adobe Portable Document Format